Chronic Lymphocytic Leukemia

Jennifer Woyach, MD, discusses the adverse events that differentiate the toxicity profiles of the treatments that are available in the frontline setting for patients with chronic lymphocytic leukemia.

"It’s extremely gratifying to see positive results for this important trial exploring the combination of umbralisib and ublituximab in patients with both front-line and relapsed/refractory CLL."

Alexey V. Danilov, MD, PhD, discusses a treatment regimen of venetoclax plus rituximab used for patients with chronic lymphocytic leukemia the 2019 American Society of Hematology Annual Meeting.

The longest follow-up for ibrutinib monotherapy to date maintained the benefit of the Bruton&rsquo;s tyrosine kinase inhibitor for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma across settings.<br /> &nbsp;

The appropriate gap between diagnosis of chronic lymphocytic leukemia and treatment is now clearer as a new prognostic tool, IPS-E, that can predict the length of &ldquo;watch and wait&rdquo; has been introduced, according to a press release from the American Society of Hematology.

Although fludarabine, cyclophosphamide, and rituximab may be efficient in inducing remission for the treatment of patients with Binet A high-risk chronic lymphocytic leukemia, recent data published in&nbsp;Leukemia&nbsp;suggest there is no evidence that this would be better than the current standard of care, which is the &ldquo;watch and wait&rdquo; approach.

Jeff P. Sharman, MD, discusses the secondary end points from the&nbsp;<u><strong><a href="https://www.targetedonc.com/conference/ash-2019/patients-with-cll-treated-on-the-elevatetn-trial-experience-improved-pfs-with-acalabrutinib">phase III ELEVATE-TN&nbsp;trial</a></strong></u>, which evaluated the role of acalabrutinib, either as a single agent or in combination with obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia.

Bendamustine debulking followed by ofatumumab and ibrutinib demonstrated an overall response rate of 92% in patients with chronic lymphocytic leukemia, meeting the primary end point of the phase II CLL2-BIO trial, and was well-tolerated with no new safety signals. Results from the study were published in&nbsp;Haematologica.

Alexey V. Danilov, MD, PhD, discusses important studies in the chronic lymphocytic leukemia space and questions whether combination or sequential therapy is better for patients with chronic lymphocytic leukemia.

In an interview with Targeted Oncology, Alexey V. Danilov, MD, PhD, discussed the ELEVATE-TN trial and other potentially practice-changing BTK inhibitor combinations expected to emerge in chronic lymphocytic leukemia.